|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy显示文摘Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) is well known to be associated with significant adverse effects. Sensorineural hearing loss, that in most cases is unilateral, has been reported as a consequence of therapy with both non-pegylated and pegylated interferon (pegIFN) but is not a well-known adverse effect. We report a 45-year-old Caucasian woman who developed acute sensorineural hearing loss 2 mo after starting therapy with pegIFN-α 2b and ribavirin for the treatment of chronic HCV, genotype 1a. She did not report the hearing loss to the hepatitis clinic until L mo,later whereupon therapy was promptly discontinued.Although her serum alanine aminotransferase (ALT)normalized and her HCV-RNA became undetectable after 12 wk of pegIFN and ribavirin therapy, after discontinuation,her HCV-RNA became detectable with significant elevations of serum ALT. Four months after initial discontinuation,the patient re-commenced pegIFN and ribavirin combination therapy. After 44 of 48 wk of therapy, the patient's liver biochemistry has normalized and the HCV-RNA is undetectable. She has not developed worsening of her hearing loss and hearing on the left-side is unaffected.Both patients and physicians should be aware that sensorineural hearing loss may occur with pegIFN therapy.Our experience suggests that re-institution of therapy is not always associated with further hearing impairment. | Victor K Wong Cindy Cheong-Lee Jo-Ann E Ford Eric M Yoshida | 2005 | World Journal of Gastroenterology2005，11，34： | 2 |
| 2 | A technique to quantify the population size and composition of the biofilm component in communities of bacteria in the phyllosphere 显示文摘 | CINDY E M MONIER J M JACQUES M A | 1998 | Microbiology1998，64，12： | 1 |
| 3 | A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults 显示文摘 | Eric E Mast Cindy M Weinbaum Anthony E Fiore | 2006 | MMWR2006，24，1： | 1 |
| 4 | A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices(ACIP) PartlI :Immunization of Adults显示文摘 | Eric E M Cindy M W Anthony E F | 2006 | MMWR2006，55，8： | 1 |
| 5 | A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices(ACIP) Part Ⅱ:Immunization of Adults显示文摘 | Cindy M W Anthony E F | 2006 | MMWR2006，55，8： | 1 |
| 6 | Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C显示文摘一估计世界范围的 3 亿个人在加拿大与一般人口的 0.8%-1.0% 的流行受不了长期的丙肝。证据的一个增加的水池存在为丙肝支持 pegylated- 干扰素(pegIFN ) 和 ribavirin 联合治疗的使用。我们与长期的丙肝(遗传型 2b ) 报导北美的土著的降下的 49 年的老男性。活体检视证实他与左眼疼痛的 2-wk 历史有肝硬化并且减少视敏度。他在 pegIFN-alpha 2a 和 ribavirin 联合治疗的 24 wk 中的 16 个以后得了网膜的静脉血栓。他是着急地指了一位网膜的专家并且与 non-ischemic 诊断了左眼的中央网膜的静脉吸藏。PegIFN 和 ribavirin 联合治疗被中止, HCV RNA 在处理的 16 wk 以后是无法发现的。Hematologic 调查表明病人是有温和地减少的蛋白质 C 活动的第五因子 Leiden 异质接合体。我们的病人有很多个亢奋的可凝结的风险因素,包括将很可能独自仍然保持临床上沉默的第五因子 Leiden 杂合现象,肝硬化,和丙肝。我们推测在 pegIFN 治疗的背景,这些冒因素的风险,这可以联合并且引起网膜的静脉血栓。 | Iman Zandieh Mohamed Adenwalla Cindy Cheong-Lee Patrick E Ma Eric M Yoshida | 2006 | World Journal of Gastroenterology2006，12，30： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员